-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Initiates Coverage On Amneal Pharmaceuticals with Outperform Rating, Announces Price Target of $27

Benzinga·09/23/2026 12:10:33
Listen to the news
Oppenheimer analyst Les Sulewski initiates coverage on Amneal Pharmaceuticals (NASDAQ:AMRX) with a Outperform rating and announces Price Target of $27.